Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Psychotherapy for Self-Disorders in Schizophrenia Spectrum Disorder (VITALIZE)

21 września 2026 zaktualizowane przez: Sidse Arnfred, Psychiatric Research Unit, Region Zealand, Denmark

Psychotherapy for Abnormalities of Self-VITALITY in Patients With Schizophrenia Spectrum Disorder: A Feasibility RCT [VITALIZE]

The primary goal of the VITALIZE study is to evaluate the feasibility of SELF-7, a novel phenomenologically informed psychotherapy for self-disorders, as an add-on to standard psychiatric outpatient treatment - Flexible Assertive Community Treatment (F-ACT) - in adults with schizophrenia spectrum disorders. The main question is whether SELF-7 is feasible and acceptable in routine psychiatric outpatient care (F-ACT teams). A secondary objective of the study is to explore whether SELF-7 may reduce psychological distress related to self-disorders and improve personal recovery, well-being, functioning, perceived stress, suicidal ideation, symptom severity, insight, and self-disorders. Researchers will compare SELF-7 plus F-ACT with F-ACT alone. Participants will be randomized to one of the two groups, complete clinical interviews and questionnaires at baseline, 16 weeks, and 26 weeks, and, if allocated to SELF-7, receive 12 individual psychotherapy sessions in addition to standard care (F-ACT).

Przegląd badań

Status

Jeszcze nie rekrutacja

Warunki

Interwencja / Leczenie

Szczegółowy opis

Schizophrenia spectrum disorders (SSD) are associated with self-disorders, a group of non-psychotic, trait-like phenomena considered close to the psychopathological core of SSD. Systematic reviews and meta-analyses have consistently demonstrated high levels of self-disorders in individuals with SSD. Although cognitive behavioral therapy (CBT) is recommended as an adjunctive psychological treatment for schizophrenia, meta-analytic evidence suggests that its efficacy is limited. It has been proposed that this may reflect a mismatch between psychotherapeutic approach and the psychopathological core of SSD. Consequently, there is a need to develop and evaluate psychotherapeutic interventions that are more closely tailored to these core features.

SELF-7 is a novel, manualized, phenomenologically informed psychotherapeutic intervention with integrated psychoeducational components targeting self-disorders in SSD. The intervention was developed from the Seven Step Phenomenological Psychotherapy for Self-Disorder (SSPP-SD), drawing on extensive clinical experience in Norway and further refined through pilot projects conducted in Norway and Denmark. SELF-7 is delivered according to a manual comprising seven thematic modules and is designed to support patients' awareness, understanding, and coping with difficulties related to self-disorders, while strengthening adaptive coping, facilitating change, and supporting coherence in self-experience.

The VITALIZE study is a two-arm, parallel, randomized controlled feasibility trial investigating SELF-7 as an add-on to standard outpatient treatment delivered through Flexible Assertive Community Treatment (F-ACT) teams. The primary objective is to examine the feasibility of SELF-7 for patients with SSD in an outpatient setting. The secondary objective is to explore preliminary clinical effects of the intervention.

Forty adult patients with schizophrenia (ICD-10 F20.x) or schizotypal disorder (ICD-10 F21) who have been discharged from OPUS, an early intervention outpatient programme, within the previous five years and are currently receiving treatment in an F-ACT team will be randomized in a 1:1 ratio to either SELF-7 plus F-ACT or F-ACT alone.

Participants allocated to SELF-7 will receive 12 sessions of individual psychotherapy preceded by an Examination of Anomalous Self-Experience (EASE) interview. Therapy will be delivered by trained research therapists while participants continue to receive standard F-ACT throughout the intervention period. Participants allocated to the control group will continue receiving F-ACT alone.

As the primary aim of the study is to assess feasibility, feasibility outcomes constitute the primary trial outcomes. Feasibility will be evaluated across five predefined domains: acceptability, adherence, patient satisfaction, patient and therapist evaluations, and adverse events. These outcomes will be used to determine whether progression to a future definitive randomized controlled trial is justified.

The primary exploratory outcome is change in psychological distress related to self-disorders, measured using the Psychological Outcome Profiles for Self-Disorders (PSYCHLOPS-SD). Secondary exploratory outcomes include personal recovery, well-being, perceived stress, suicidal ideation, functioning, symptom severity, insight, and self-disorders.

Outcome assessments will be conducted at baseline before randomization (T0), at 16 weeks post-allocation (T1), and at follow-up 26 weeks post-allocation (T2). Data collection includes clinician-rated assessments and participant-reported questionnaires. The PhD investigator conducting baseline and follow-up clinician-rated assessments will remain blinded to treatment allocation, whereas therapists and participants cannot be blinded because of the nature of the study. Statistical analyses will be conducted by an independent statistician with treatment allocation concealed during the primary analyses.

The VITALIZE study will provide original knowledge regarding the feasibility and potential clinical utility of a phenomenologically informed psychotherapy targeting self-disorders in SSD. If SELF-7 is found to be feasible and supported by improvements in exploratory outcomes, the findings may inform the design, outcome selection, and sample size calculation of a future definitive randomized controlled trial.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

40

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

Lokalizacje studiów

    • Region Sjælland
      • Slagelse, Region Sjælland, Dania, 4200
        • Psychiatric Research Unit, Mental Health Services Region Zealand
        • Kontakt:
        • Kontakt:
        • Główny śledczy:
          • Sidse Marie Arnfred, Professor

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 50 lat (Dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Age ≥18 years.
  • Capacity to understand study procedures and provide written informed consent.
  • ICD-10 diagnosis of schizophrenia (F20.x) or schizotypal disorder (F21).
  • Receiving treatment in a Flexible Assertive Community Treatment (F-ACT) team.
  • Discharged from the OPUS early intervention outpatient programme within the past 5 years.
  • Clinically stable with regard to antipsychotic treatment (receiving antipsychotic medication or not receiving antipsychotic medication) and with no planned substantial changes in antipsychotic treatment at the time of inclusion.

Exclusion Criteria:

  • Insufficient proficiency in Danish to participate in psychotherapy and complete study assessments.
  • Current severe alcohol or substance dependence.
  • Current forensic psychiatric status.
  • Clinically assessed elevated risk of severe self-harm, suicide, or harm to others.
  • Severe comorbid somatic illness or severe comorbid psychiatric disorder that substantially compromises the ability to participate in psychotherapy.
  • Not deemed able to participate in psychotherapy based on clinical judgment.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Podwójnie

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: SELF-7 Intervention + F-ACT

SELF-7 psychotherapeutic intervention as add-on to standard outpatient Flexible Assertive Community Treatment (F-ACT)

SELF-7 is a manualized, phenomenologically informed psychotherapeutic intervention with integrated psychoeducational components targeting self-disorders in schizophrenia spectrum disorders. The intervention is delivered according to a manual comprising seven therapeutic modules and constitutes a therapeutic framework that supports patients' awareness, understanding, and coping with difficulties related to self-disorders. While manualized, the therapeutic process is flexible and may move back and forth between modules to meet individual patient needs. SELF-7 aims to support coherence in self-experience, strengthen adaptive coping, and facilitate change. The intervention consists of 12 individual psychotherapy sessions preceded by an Examination of Anomalous Self-Experience (EASE) interview and is delivered as an add-on to standard Flexible Assertive Community Treatment (F-ACT).

Flexible Assertive Community Treatment (F-ACT) is the standard outpatient treatment provided in the participating mental health services. F-ACT includes medical consultations, regular contact with a designated case manager, and network and coordination meetings. The model is flexible, allowing the intensity of care, including consultations and home visits, to be increased according to clinical need. Participants continue receiving F-ACT throughout the study period.

Aktywny komparator: F-ACT alone

Standard outpatient Flexible Assertive Community Treatment (F-ACT) alone

Flexible Assertive Community Treatment (F-ACT) is the standard outpatient treatment provided in the participating mental health services. F-ACT includes medical consultations, regular contact with a designated case manager, and network and coordination meetings. The model is flexible, allowing the intensity of care, including consultations and home visits, to be increased according to clinical need. Participants continue receiving F-ACT throughout the study period.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Acceptability
Ramy czasowe: From eligibility assessment to randomization

Acceptance of study participation. Defined as the proportion of eligible participants who provide written informed consent and are subsequently randomized. This outcome assesses the feasibility of recruitment procedures and the acceptability of trial participation among the target population. Feasibility will be considered acceptable if at least 50% of eligible patients are enrolled and randomized.

From eligibility assessment to randomization
Adherence
Ramy czasowe: From inclusion (week 0) to end-of-therapy (week 16)

Adherence to the SELF-7 psychotherapeutic intervention. Defined as the proportion of participants allocated to SELF-7 who complete at least 10 psychotherapy sessions. This outcome assesses feasibility of intervention delivery and participant engagement with treatment. Feasibility will be considered acceptable if at least 70% of intervention participants complete a minimum of 10 sessions.

From inclusion (week 0) to end-of-therapy (week 16)
Patient Satisfaction
Ramy czasowe: At end of therapy (week 16)

Patient satisfaction with the SELF-7 intervention assessed using the Client Satisfaction Questionnaire-8 (CSQ-8) at end of therapy (week 16). The CSQ-8 is an 8-item self-report measure of perceived quality, usefulness, and acceptability of care. Higher scores indicate greater satisfaction with treatment. Feasibility will be considered acceptable if at least 70% of participants achieve a mean CSQ-8 score greater than 3.5.

At end of therapy (week 16)
Participant Evaluation
Ramy czasowe: End of therapy (week 16)

Participant evaluation of the SELF-7 intervention assessed using the purpose-developed patient version of SELF-7 Treatment Feedback Scale (STFS). The patient version of STFS is a 4-item participant-rated measure assessing perceived therapeutic understanding, relevance of therapeutic content, usefulness of the therapeutic approach, and overall benefit of SELF-7 for understanding and managing self-disorders. Items are rated on an 11-point scale ranging from 0 ("not at all") to 10 ("to a very high degree"). Mean scores range from 0 to 10, with higher scores indicating more positive evaluations and greater acceptability of the intervention. Feasibility will be considered acceptable if at least 70% of participants provide overall positive feedback.

End of therapy (week 16)
Therapist Evaluation
Ramy czasowe: At end of therapy (week 16)

Therapist evaluation of the SELF-7 intervention assessed using the purpose-developed terapist version of SELF-7 Treatment Feedback Scale (STFS). The terapist version of STFS is a 4-item therapist-rated measure assessing therapeutic alliance and collaboration, relevance of therapy content, appropriateness of the therapeutic approach, and the overall contribution of SELF-7 to the patient's understanding and management of self-disorders. Items are rated on an 11-point scale ranging from 0 ("not at all") to 10 ("to a very high degree"). Mean scores range from 0 to 10, with higher scores indicating more positive evaluations and greater acceptability of the intervention. Feasibility will be considered acceptable if at least 70% of therapists provide overall positive feedback.

At end of therapy (week 16)
Adverse Effects
Ramy czasowe: From inclusion (week 0) until end of therapy (week 16)

Therapy-related adverse effects will be assessed at end of therapy using the Negative Effects Questionnaire (NEQ-20), a 20-item self-report measure designed to assess unwanted and adverse effects associated with psychological treatment. The NEQ-20 will be used to evaluate the safety and tolerability of the SELF-7 intervention, alongside monitoring of serious therapy-related adverse events. Items are rated on a 5-point scale, and mean scores range from 0 to 4, with higher scores indicating more frequent and/or severe negative effects of treatment. A mean score of 0 indicates no reported negative effects, whereas a mean score of 4 indicates the highest level of reported negative effects. The adverse effects criterion is met if no more than one serious therapy-related adverse event (as defined in the protocol) occurs during the intervention period (week 0 - week 16) and if fewer than 10% of participants have a mean NEQ-20 score greater than 2 measured at end of therapy (week 16).

From inclusion (week 0) until end of therapy (week 16)

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Psychological Outcome Profiles (PSYCHLOPS)
Ramy czasowe: T0 (baseline pre-allocation), T1 (16 weeks post-allocation), and T2 (26 weeks post-allocation)

Psychological Outcome Profiles (PSYCHLOPS), an individualized idiographic patient-reported outcome measure (I-PROM) that measures psychological distress, and will serve as the primary exploratory outcome. PSYCHLOPS includes four items covering three domains: (1) Problems; (2) Function; and (3) Well-being. A six-point rating scale is used to score the intensity and duration of psychological distress. PSYCHLOPS is adapted to assess psychological distress related to self-disorders, as participants follow a structured procedure that guides them in identifying and rating their main self-defined psychological problems and associated distress related to self-disorder phenomena. Higher scores indicate greater psychological distress related to self-disorders.

T0 (baseline pre-allocation), T1 (16 weeks post-allocation), and T2 (26 weeks post-allocation)
Readiness for Psychotherapy (RPI)
Ramy czasowe: Baseline (pre-allocation)

The RPI is a self-report measure to assess seven dimensions of readiness for psychotherapy: level of distress, desire for change, willingness to work in therapy, recognition of problems as psychological, willingness to discuss personal matters, willingness to endure discomfort in therapy, and responsibility for change. 42 items; 5-point Likert scale. 7 subscales; total score and subscale scores are analyzed; higher scores indicate greater readiness.

Baseline (pre-allocation)
Personal Recovery (Brief INSPIRE-O)
Ramy czasowe: Baseline (pre-allocation), end of therapy (week 16), and follow-up (week 26)

The Brief INSPIRE-O is a patient-reported outcome measure assessing personal recovery across the domains of connectedness, hope, identity, meaning, and empowerment (CHIME). The instrument consists of 10 items covering five domains, rated on a 5-point Likert scale. Total scores range from 10 to 50. Higher scores indicate greater perceived personal recovery.

Baseline (pre-allocation), end of therapy (week 16), and follow-up (week 26)
The WHO Well-Being Index (WHO-5)
Ramy czasowe: Baseline (pre-allocation), end of therapy (week 16), and follow-up (week 26)

The WHO Well-Being Index (WHO-5) is a self-report measure of current subjective psychological well-being. The instrument consists of 5 items rated on a 6-point Likert scale. Raw scores range from 0 to 25 and are transformed to a scale ranging from 0 to 100. Higher scores indicate better well-being.

Baseline (pre-allocation), end of therapy (week 16), and follow-up (week 26)
The Perceived Stress Scale (PSS-10)
Ramy czasowe: Baseline (pre-allocation), end of therapy (week 16), and follow-up (week 26)

The Perceived Stress Scale (PSS-10) is a self-report questionnaire assessing the degree to which individuals perceive their lives as stressful, unpredictable, and overloaded during the past month. The instrument consists of 10 items rated on a 5-point Likert scale. Total scores range from 0 to 40. Higher scores indicate greater perceived stress.

Baseline (pre-allocation), end of therapy (week 16), and follow-up (week 26)
The Suicidal Ideation Attributes Scale (SIDAS)
Ramy czasowe: Baseline (pre-allocation), end of therapy (week 16), and follow-up (week 26)

The Suicidal Ideation Attributes Scale (SIDAS) is a self-report measure assessing the severity and impact of suicidal ideation, including frequency, controllability, distress, and interference with daily functioning. The instrument consists of 5 items rated on 11-point scales. Total scores range from 0 to 50. Higher scores indicate greater suicidal ideation severity.

Baseline (pre-allocation), end of therapy (week 16), and follow-up (week 26)
The Personal and Social Performance Scale (PSP)
Ramy czasowe: Baseline (pre-allocation) and follow-up (week 26)

The Personal and Social Performance Scale (PSP) is a clinician-rated measure assessing functioning across four domains: socially useful activities, personal and social relationships, self-care, and disturbing/aggressive behaviors. Total scores range from 1 to 100. Higher scores indicate better personal and social functioning.

Baseline (pre-allocation) and follow-up (week 26)
The Scale for the Assessment of Positive Symptoms (SAPS)
Ramy czasowe: Baseline (pre-allocation) and follow-up (week 26)

The Scale for the Assessment of Positive Symptoms (SAPS) is a clinician-rated instrument assessing the severity of positive psychotic symptoms, including hallucinations, delusions, bizarre behavior, and positive formal thought disorder. The instrument consists of 34 items across four global domains and includes both item-level and global domain ratings. Items are rated on a 6-point scale (0-5). Higher scores indicate greater positive symptom severity, with a score of 0 reflecting the absence of positive symptoms and higher scores reflecting increasing symptom severity.

Baseline (pre-allocation) and follow-up (week 26)
The Brief Negative Symptom Scale (BNSS)
Ramy czasowe: Baseline (pre-allocation) and follow-up (week 26)

The Brief Negative Symptom Scale (BNSS) is a clinician-rated scale assessing core negative symptom domains, including anhedonia, asociality, avolition, blunted affect, and alogia. The instrument consists of 13 items across five domains. Each item is rated on a 7-point scale (0-6), yielding a total score ranging from 0 to 78, with higher scores indicating greater negative symptom severity. A score of 0 reflects the absence of negative symptoms, whereas higher scores reflect increasing severity of negative symptoms. Total and domain scores will be analyzed.

Baseline (pre-allocation) and follow-up (week 26)
The Positive and Negative Syndrome Scale (PANSS) Item G12
Ramy czasowe: Baseline (pre-allocation) and follow-up (week 26)

Insight assessed using Item G12 from the Positive and Negative Syndrome Scale (PANSS). G12 is a clinician-rated item evaluating awareness and understanding of having a mental illness, recognition of symptoms as pathological, and appreciation of the need for treatment. Scores range from 1 to 7. Higher scores indicate poorer insight and greater lack of judgment.

Baseline (pre-allocation) and follow-up (week 26)
The Examination of Anomalous Self-Experience (EASE)
Ramy czasowe: Baseline (pre-allocation) and follow-up (week 26)

The Examination of Anomalous Self-Experience (EASE) is a semi-structured interview comprising 57 main items distributed across five domains: Cognition and stream of consciousness, Self-awareness and presence, Bodily experiences, Demarcation/transitivism, and Existential reorientation/solipsism. Items are rated dichotomously as present or absent. Scores are summed into an EASE total score, where 1 point corresponds to the presence of 1 self-disorder item. Higher scores indicate greater levels of self-disorders.

Baseline (pre-allocation) and follow-up (week 26)

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

15 września 2026

Zakończenie podstawowe (Szacowany)

31 grudnia 2028

Ukończenie studiów (Szacowany)

31 grudnia 2028

Daty rejestracji na studia

Pierwszy przesłany

6 września 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

21 września 2026

Pierwszy wysłany (Rzeczywisty)

25 września 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

25 września 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

21 września 2026

Ostatnia weryfikacja

1 września 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • SJ-1139
  • 4309-00072B (Inny numer grantu/finansowania: Independent Research Fund Denmark)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

De-identified individual participant data (IPD) underlying the results reported in publications from the VITALIZE study may be shared after publication of the primary study results. Shared data may include participant-level data from feasibility and exploratory outcome measures, together with a data dictionary and relevant study documentation. Data will be fully de-identified prior to sharing to protect participant confidentiality and will be shared in accordance with applicable Danish data protection regulations, ethical approvals, and institutional policies. Data containing information that could increase the risk of participant re-identification will not be shared. The study is conducted in accordance with the General Data Protection Regulation (GDPR) and the Danish Data Protection Act. Requests for access to de-identified individual participant data should be directed to the Principal Investigator or study team. Data may be available upon request under a data-sharing agreement.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .